GlassScriptPhysician profile
Kelly Lambeth
NPI 1215232343
$2,757.83
in general payments reported to CMS, 2019-2025
27 companies · $723 in 2025
The $723 reported for 2025 was more than what 80% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $308 · 2022: $516 · 2023: $773 · 2024: $438 · 2025: $723.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,933.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,933.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $943.87 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Exact Sciences Corporation | $267.22 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Abbvie INC. | $265.10 | 2023-2025 | |
| Lilly USA, LLC | $229.02 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $208.26 | 2021-2023 | Farxiga |
| Sanofi-Aventis U.S. LLC | $134.78 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $100.53 | 2022-2024 | Trintellix |
| Alpha Cognition USA, INC. | $94.85 | 2025 | Zunveyl |
| Glaxosmithkline, LLC. | $85.32 | 2021-2023 | Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $64.37 | 2024-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $47.09 | 2021-2022 | |
| Abbott Laboratories | $39.02 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Organon LLC | $37.56 | 2025 | Nexplanon |
| Azurity Pharmaceuticals, INC. | $31.83 | 2023 | Adthyza |
| Merck Sharp & Dohme LLC | $25.72 | 2023 | Dificid |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medline Industries LP | $18.51 | 2023 | |
| Mayne Pharma Commercial LLC | $18.09 | 2023 | |
| Novartis Pharmaceuticals Corporation | $17.60 | 2022 | |
| Avanir Pharmaceuticals, INC. | $17.03 | 2022 | |
| Axsome Therapeutics, INC. | $15.91 | 2023 | Auvelity |
| Hologic Sales and Service, LLC | $15.77 | 2025 | Aptima |
| Therapeuticsmd, INC. | $15.45 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.93 | 2022 | |
| Mycovia Pharmaceuticals, INC. | $14.04 | 2023 | Vivjoa |
| Pfizer INC. | $13.63 | 2025 | |
| Esperion Therapeutics, INC. | $13.25 | 2024 | Nexletol |
| Genentech USA, INC. | $9.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Lambeth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.